(NASDAQ: CYCC) Cyclacel Pharmaceuticals's forecast annual revenue growth rate of 549.49% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 39.22%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Cyclacel Pharmaceuticals's revenue in 2024 is $420,000.On average, 2 Wall Street analysts forecast CYCC's revenue for 2026 to be $191,015,439, with the lowest CYCC revenue forecast at $73,809,209, and the highest CYCC revenue forecast at $308,221,669. On average, 1 Wall Street analysts forecast CYCC's revenue for 2027 to be $151,691,833, with the lowest CYCC revenue forecast at $151,691,833, and the highest CYCC revenue forecast at $151,691,833.
In 2028, CYCC is forecast to generate $211,092,493 in revenue, with the lowest revenue forecast at $211,092,493 and the highest revenue forecast at $211,092,493.